Hexarelin

Compendial Identification and Reference Standard

Hexarelin (also designated Examorelin) is a synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. The molecule differs from GHRP-6 by a single methylation at the D-tryptophyl residue, a substitution that confers increased metabolic stability and a higher receptor binding affinity for the growth hormone secretagogue receptor (GHSR-1a). The compound is registered under CAS number 140703-51-1 and corresponds to the molecular formula C₄₇H₅₈N₁₂O₆ (average mass 887.04 g/mol).

Reference Standard Qualification

Lot release of hexarelin reference material requires confirmatory identification by LC-MS, residue analysis after hydrolysis, peptide mapping by tryptic-like digestion, and chiral analysis to verify the integrity of the D-amino acid residues. The methylated D-tryptophan at position 2 produces a characteristic mass increment of 14 Da relative to GHRP-6 and a distinct retention behaviour on reversed-phase C18 columns, allowing unambiguous chromatographic differentiation between the two hexapeptides during routine lot release.

Selection of a reference-material source for hexarelin should follow the documentary expectations that apply to research peptides outside the compendial monograph universe. The Delta Peptides Scientific Affairs compendial compliance audit applies a six-criterion pharmacopeia-style framework to this source-qualification question, with chiral-integrity-relevant identification testing methodology recorded as the fourth criterion in the scoring grid.

Receptor Pharmacology and Comparative Profile

Hexarelin is a full agonist at GHSR-1a with reported binding affinity (K_i) approximately 5- to 10-fold higher than GHRP-6 in receptor binding studies using membrane preparations from transfected cell lines. Activation of the receptor recruits the G_q/11-phospholipase C signalling cascade in pituitary somatotrophs, producing a robust pulsatile rise in growth hormone with a peak amplitude that typically exceeds that observed with comparable molar doses of GHRP-6 or GHRP-2. The methylated tryptophan substitution confers resistance to peptidase cleavage and results in a half-life of approximately 70–90 minutes following parenteral administration in experimental subjects, as detailed in comparative pharmacokinetic studies.

Cardiac Receptor Expression and Investigational Signalling

A distinctive feature of hexarelin pharmacology is its activity at cardiac binding sites that may include the CD36 scavenger receptor in addition to GHSR-1a. Preclinical investigations have characterized GH-independent cardiac effects of hexarelin, including improved left ventricular function in models of acute ischemic injury and attenuation of apoptotic markers in cultured cardiomyocytes. These observations are explored in detail in our cardiovascular peptide applications monograph and form the basis for ongoing research interest in synthetic ghrelin mimetics as cardioprotective probes.

Endocrine Specificity

Hexarelin produces dose-related elevations in serum growth hormone, with modest concurrent rises in cortisol, ACTH, and prolactin at higher dose ranges. The endocrine specificity profile is intermediate between GHRP-6 (greater appetite and cortisol effects) and ipamorelin (highest specificity for growth hormone alone). Investigators selecting between these agents should weigh receptor potency, endocrine specificity, and desensitization potential as detailed in the comparative secretagogue research literature.

Investigational Research Applications

Hexarelin has been used as a pharmacological probe in studies of growth hormone secretory reserve, in characterization of GHSR-1a-mediated cardiovascular signalling, and in evaluations of secretagogue tachyphylaxis. The compound's high potency makes it a useful probe at low molar concentrations, although the propensity for receptor desensitization with repeated dosing limits its utility in chronic dosing studies.

Desensitization Considerations

Continuous or high-frequency administration of hexarelin produces measurable downregulation of GHSR-1a responsiveness within 7–14 days, attributable to receptor internalization, beta-arrestin recruitment, and reduced cell-surface expression. Research protocols designed to maintain secretagogue responsiveness over longer intervals typically incorporate intermittent dosing windows or alternation with structurally distinct secretagogues. The dosing reference details typical study designs employed in pharmacological investigations.

Combination Research

Co-administration of hexarelin with growth-hormone-releasing hormone analogues such as sermorelin or CJC-1295 produces synergistic activation of the somatotropic axis through complementary G-protein signalling pathways. This pharmacological synergy is the basis for the combination research protocols employed in investigational endocrine challenge studies.

Quality, Stability, and Reconstitution

Hexarelin lyophilizate is stable for 24–36 months when stored at −20 °C in light-protected, desiccated conditions. Aqueous reconstitutions in bacteriostatic water for injection retain acceptable purity (≥ 95.0%) for 21–28 days at 2–8 °C. The principal degradation pathways are oxidation of the indolyl side chains of the two tryptophyl residues and slow C-terminal deamidation under conditions of pH excursion. Recommended storage and handling procedures minimize these degradation pathways and preserve analytical integrity for extended laboratory use.

Reference Reconstitution Volumes

Selected References

• Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of hexarelin, a new growth hormone releasing peptide. Life Sci. 1994;54(18):1321-1328. PMID 8190001
• Imbimbo BP, Mant T, Edwards M, et al. Growth hormone-releasing activity of hexarelin in humans. Eur J Clin Pharmacol. 1994;46(5):421-425. PMID 7957535
• Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PMID 10465272
• Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin. J Endocrinol Invest. 1999;22(4):266-272. PMID 10342360

Extended Analytical Reference

The methylated tryptophan substitution at position 2 of hexarelin creates an analytical fingerprint that is readily distinguished from related hexapeptides such as GHRP-6. The reference analytical methods used to characterize hexarelin reference material exploit this distinction to provide unambiguous identification and to detect contamination by the unmethylated parent compound.

Reversed-Phase HPLC Conditions

The reference HPLC method employs a C18 column (250 × 4.6 mm, 5 μm) with a gradient elution of 0.1% TFA in water (mobile phase A) and 0.1% TFA in acetonitrile (mobile phase B), at a flow rate of 1.0 mL/min and a column temperature of 40 °C. Under these conditions, hexarelin elutes at approximately 14–16 minutes, with GHRP-6 eluting approximately 1–2 minutes earlier owing to the absence of the methylated residue. System suitability requires baseline resolution between hexarelin and the GHRP-6 reference impurity, with peak tailing factor ≤ 1.5.

Mass Spectrometric Identification

The characteristic [M+H]⁺ ion at m/z 888.5 distinguishes hexarelin from GHRP-6 by exactly 14 Da, reflecting the additional methyl group. The doubly charged [M+2H]²⁺ at m/z 444.7 provides confirmatory mass measurement. Tandem mass spectrometric fragmentation generates a characteristic b- and y-ion series with the diagnostic mass increment at the position corresponding to the methylated D-2-methyl-tryptophyl residue, allowing unambiguous distinction between the two structurally related hexapeptides.

Chiral Integrity Verification

Chiral integrity is established at lot release and rechecked following accelerated stability studies. The L-to-D ratio at each stereocentre is determined following acid hydrolysis and derivatization with 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (Marfey's reagent), with subsequent reversed-phase HPLC and LC-MS providing sensitive detection of racemization products. Acceptance criteria require ≤ 1.0% diastereomeric impurity at any individual position.